A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Registry ID

EUCTR2009-012787-14

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Bayer HealthCare AG

Start date

2010-07-26

Last update

2026-08-16

Conditions

• Metastatic Colorectal Carcinoma
• Metastatic Colorectal Carcinoma Cáncer Colorectal Metastásico

Summary

To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies. The primary efficacy endpoint of this study is Overall survival

Locations

• , , Belgium
• , , Germany
• , , Hungary
• , , Portugal
• , , Spain
• , , Czechia
• , , Italy
• , , France
• , , Netherlands

Related clinical trials

• Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
• An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

View on source registry